Scott Manalis, collaborating with Dana-Farber Cancer Institute's Keith Ligon, has developed a technique to measure single-cell density for predicting whether immunotherapies will work in a patient or how a tumor will respond to drug treatment. This method, detailed in Nature Biomedical Engineering, originated as a project funded in part by the MIT Center for Precision Cancer Medicine.